“…This study purports to investigate the influence of factors such as sex, age, type of vaccination (Comirnaty, BNT162b2, Pfizer Inc. or Vaxzevria, ChAdOx1-S, Oxford/AstraZeneca), and time since vaccine administration on the process of antibody production. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Here we describe an innovative partnership between Alexion, AstraZeneca Rare Disease and patients that allowed a deeper understanding of the biopharmaceutical stakeholder ecosystem and an empathic understanding of each patient’s and caregiver’s lived experience. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We highlight a range of post-COVID-19 vaccination CNS MRI findings, including CVST, with a higher incidence in individuals receiving the ChAdOx1 (AstraZeneca) vaccine. Other notable observations include cases of ADEM, myelitis or transverse myelitis (TM), Guillain–Barré syndrome (GBS), and acute encephalopathy following COVID-19 vaccination. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…To develop an approach that can readily be applied to future trials by AstraZeneca and other trial sponsors. DESIGN: Life cycle assessment including all the sources of carbon emissions associated with a completed, an ongoing and a planned clinical trial. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Chronic urticaria occurred following Pfizer-BioNTech, AstraZeneca, and Janssen Ad26.COV2.S vaccination in 6, 1, and 1 patient, respectively, with a median of 12 days (IQR, 3-38) from vaccination to symptoms onset. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…As many as 209 (85.3%) and 141 (96.6%) participants were seropositive for receiving CoronaVac and AstraZeneca, respectively. Meanwhile, all participants receiving two-dose CoronaVac with one booster dose of Moderna (105/100%) were seropositive (p < 0.05). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The Comirnaty-Pfizer/BioNTech vaccine (COM) was the most administered vaccine in all EU/EEA countries, followed by the Moderna mRNA-1273 vaccine (MOD) and the Astra-Zeneca-Vaxzevria vaccine (AZ). The Janssen-Ad26.COV 2.5 vaccine (Janss) use ranged from 0.1% to 4.8% for the one dose vaccine. …”
Enlace del recurso
Enlace del recurso

“…The medicine in question was carefully developed by the esteemed pharmaceutical company AstraZeneca. The FDA granted authorization on 21 November 2019 for the utilization of acalabrutinib (ACB) in the treatment of small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) in adult patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DISCLOSURES: Tanya Rogo, MD, AstraZeneca: Grant/Research Support|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support…”
Enlace del recurso
Enlace del recurso

“…BACKGROUND: In May 2000, AstraZeneca launched a Web service for asthma patients and health-care providers called LinkMedica, which includes an asthma diary for monitoring and self-management. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…‘Iressa’ is a trademark of the AstraZeneca group of companies. We have previously demonstrated a synergistic interaction between ZD1839 and cisplatin/5-fluorouracil (5FU) in CAL33, a human head and neck cancer cell line that markedly expresses EGFR. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…INVESTIGATIONAL PRODUCT: Rosuvastatin (Crestor(®); Astra Zeneca). ACTIVE INGREDIENTS: Rosuvastatin (5 mg). …”
Enlace del recurso
Enlace del recurso

“…TRIAL REGISTRATION: NCT00496509 (ClinicalTrials.gov); D4200C00050 (AstraZeneca)…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…These third-generation aromatase inhibitors (letrozole/Femara (Novartis Pharmaceuticals, Basel, Switzerland) and anastrozole/Arimidex (AstraZeneca, Pharmaceuticals, Macclesfield, Cheshire, UK)), have recently demonstrated superior efficacy compared with tamoxifen as initial therapy for early breast cancer improving disease-free survival. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Addition of raltitrexed (Astra Zeneca, Alderley Edge, Cheshire, UK) increased the incorporation of S(4)TdR into DNA (up to 20-fold at IC(5)) and further sensitised cells to UVA. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…During the last several years major pharmaceutical companies raced to acquire antibody companies, with a recent example of MedImmune being purchased for $15.6 billion by AstraZeneca. These therapeutic and business successes reflect the major advances in antibody engineering which have resulted in the generation of safe, specific, high-affinity, and non-immunogenic antibodies during the last three decades. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We identified candidate markers for this purpose for olaparib (AstraZeneca) by measuring inhibitory effects of nine concentrations of olaparib in 22 breast cancer cell lines and identifying features in transcriptional and genome copy number profiles that were significantly correlated with response. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: In 2,250 asthma patients randomized to treatment with budesonide/formoterol or fluticasone/salmeterol in a six-month study (AstraZeneca study code: SD-039-0735), sequence diversity in the ADRB2 poly-C repeat region was determined using a novel sequencing-based genotyping method. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Given the encouraging response rate, alternative scheduling and dosing strategies should be considered (funded by AstraZeneca; ClinicalTrials.gov, NCT00707707).…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks® Quattro™ screens when detecting block of I(Kr) (hERG), I(Na) (NaV1.5), I(CaL) (CaV1.2), I(Ks) (KCNQ1/minK) and I(to) (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR® Tetra fluorescence screen for I(CaL) (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. We examined how screening variability propagates through in-silico action potential models for whole cell electrical behaviour, and how confidence intervals on model predictions can be estimated with repeated simulations. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso